When insured customers are charged a higher copay for a drug than its actual cost, it is often the result of a “clawback.” In these instances, using your health insurance doesn’t save you money.
Keller Rohrback L.L.P. and Interim Co-Lead Counsel filed a consolidated class action complaint against the top four Pharmacy Benefit Managers (“PBMs”).
Keller Rohrback L.L.P. is investigating claims that Enhancements Lash Boost, an eyelash conditioning serum that advertises lashes that can “appear longer, fuller, and darker,” is causing adverse reactions that Rodan + Fields failed to warn ...
Researchers recently found that chip flaws known as Meltdown and Spectre were putting almost every computer at risk – most personal computers are powered by Intel or AMD chips. The patches issued to correct the security flaws may be causing more ...
Mylan NV may be significantly overcharging patients for its EpiPen allergy shot. Since Mylan acquired the drug in 2007, the price has increased six-fold, from $100 to $600 for two doses. Yet Mylan pays only $34.50 per pen.
Keller Rohrback L.L.P., on behalf of the City of Tacoma, filed suit against Purdue Pharma, Endo Pharmaceuticals and Janssen Pharmaceuticals, three of the biggest manufacturers of prescription opioids in the United States.
Keller Rohrback is currently acting as co-lead counsel in Contreras v. Nationstar Mortgage L.L.C., a class action lawsuit filed against Nationstar Mortgage L.L.C.
